Skip to main content

Table 1 Baseline Characteristics and Concomitant Medications

From: Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial

Characteristic

Treatment group

P value

GXST (n = 143)

Placebo (n = 144)

Demographics

   

 Gender (M/F)

(73/70)

(82/62)

0.16

 Age (years)

56.6 ± 8.1

55.3 ± 8.3

0.15

 Height (cm)

166.6 ± 7.7

167.5 ± 7.7

0.31

 Weight (kg)

68.9 ± 10.2

68.9 ± 9.8

1.00

 HR (beats/min)

71.2 ± 9.3

70.7 ± 9.3

0.64

 SBP (mmHg)

128.8 ± 9.7

129.0 ± 9.2

0.90

 DBP (mmHg)

80.9 ± 7.2

80.1 ± 7.7

0.41

Baseline characteristics

 Angina frequency (no. of events per week)

9.4 ± 3.2

9.0 ± 3.0

0.32

 NTG consumption (no. of pills per week)

5.8 ± 3.5

5.5 ± 3.0

0.49

 SAQ score

  Physical limitations

  Angina stability

  Angina frequency

  Treatment satisfaction

  QOL

46.8 ± 10.6

51.8 ± 11.1

51.8 ± 8.7

36.9 ± 20.0

46.5 ± 18.2

44.4 ± 19.5

48.2 ± 12.0

54.1 ± 12.0

51.0 ± 9.1

43.6 ± 21.1

47.5 ± 19.2

45.0 ± 20.4

0.28

0.08

0.42

0.09

0.64

0.81

 ETT Time to onset of chest pain (s)

430.24 ± 177.2

456.42 ± 188.72

0.71

 Time to 1 mm ST-depression (s)

235.95 ± 153.11

237.69 ± 174.34

0.96

Concomitant medication

 β-blocker

10 (7.0%)

15 (10.4)

0.15

 ACEI

3 (2.1%)

0 (0.0%)

0.06

 ARB

10 (7.0%)

8 (5.6%)

0.31

 CCB

10 (7.0%)

9 (6.3%)

0.40

 Stains

126 (88.1%)

125 (86.8%)

0.38

 Anti-platelet agents

138 (96.5%)

140 (97.2%)

0.41

  1. Each value represents the mean ± SD or the number (%)
  2. GXST, Guanxinshutong capsule; ACEI, angiotensin I converting enzyme inhibitors; ARB, angiotensin II receptor blockers; CCB, calcium channel blockers, ETT, exercise treadmill test; QOL, quality of life; SAQ, Seatntle Agina Questionnaire; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate